These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 8879890)

  • 21. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
    Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
    Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
    Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
    Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
    Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial.
    Nishiwaki M; Hosoai H; Ikewaki K; Ayaori M; Yamashita T; Shige H; Higashi K; Nashida Y; Shimizu S; Kijima F; Yokoyama M; Nakamura H;
    Clin Ther; 2013 Apr; 35(4):461-73. PubMed ID: 23490288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
    Rosenstock J; Rossi L; Lin CS; MacNeil D; Osbakken M
    J Clin Pharm Ther; 1998 Dec; 23(6):433-40. PubMed ID: 10048504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
    Chrysant SG; Littlejohn T; Izzo JL; Kereiakes DJ; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):233-43. PubMed ID: 22799613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.
    Izzo JL; Chrysant SG; Kereiakes DJ; Littlejohn Iii T; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    J Clin Hypertens (Greenwich); 2011 Dec; 13(12):873-80. PubMed ID: 22142346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
    Kereiakes DJ; Chrysant SG; Izzo JL; Littlejohn T; Melino M; Lee J; Fernandez V; Heyrman R
    Cardiovasc Diabetol; 2012 Oct; 11():134. PubMed ID: 23110471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.
    Lee HY; Kim SY; Choi KJ; Yoo BS; Cha DH; Jung HO; Ryu DR; Choi JH; Lee KJ; Park TH; Oh JH; Kim SM; Choi JY; Kim KH; Shim J; Kim WS; Choi SW; Park DG; Song PS; Hong TJ; Rhee MY; Rha SW; Park SW
    Clin Ther; 2017 Dec; 39(12):2366-2379. PubMed ID: 29150250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
    Wu SC; Liu CP; Chiang HT; Lin SL
    Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
    Weir MR; Hsueh WA; Nesbitt SD; Littlejohn TJ; Graff A; Shojaee A; Waverczak WF; Qian C; Jones CJ; Neutel JM
    J Clin Hypertens (Greenwich); 2011 Jun; 13(6):404-12. PubMed ID: 21649839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
    Calhoun DA; Lacourcière Y; Crikelair N; Jia Y; Glazer RD
    Curr Med Res Opin; 2013 Aug; 29(8):901-10. PubMed ID: 23721363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.